CCL3+ Neutrophil Signature Predicts Response to Neoadjuvant Toripalimab plus Chemotherapy in Patients with Hypopharyngeal Squamous Cell Carcinoma: A Phase II Trial.

Clin Cancer Res · 2026 · PMC13223550 · PMID 41817286

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

2D did not reach statistical significance at the per-patient level.

also in 111,027 other papers

showed a trendno p-value reported

At the whole T-cell level, Rs showed a trend toward higher cytotoxic program activity with broadly comparable exhaustion (Supplementary Fig.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.